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Introduction: Aloe Vera, a perennial herb, is being used since ancient times for the cure of various diseases and is 
recently being used in curing diabetes due to the synergistic activity of its over 75 biologically active ingredients. 
The objective of the study was to compare the antidiabetic effects of Aloe Vera whole leaf extract with standard 
antidiabetic drug Sitagliptin on streptozotocin-induced diabetic rats. 
Material and Methods: The present study was RCT, conducted at the Department of Pharmacology, Islamic 
International Medical College, Rawalpindi in collaboration with the National Institute of Health, Islamabad, 
Pakistan, from September 2019 to August 2020. A total of 40, young Sprague Dawley rats weighing between 220-
250 grams were taken and randomly divided into Group A (Normal Control) and group B.  After induction of 
Type-2 Diabetes, group B was further subdivided into 3 groups with 10 rats each: Group B1 (Diabetic Control), 
Group B2 (Aloe Vera whole Leaf Extract treated), GROUP B3 (Sitagliptin treated). Terminal Sampling was done to 
measure FBS and HbA1c on Day 60.  Statistical Analysis was done by applying SPSS version 25. A one-way 
ANOVA test was used for assessing any difference in the mean values. Post-hoc Turkey analysis was conducted 
to compare any inter-group mean differences. P-value of <0.05 was considered significant.  
Results: On completion of the study, at Day 60, mean FBS values for Rats in Group A were 82.40 mg/dl, for 
Group B1 498.40 mg/dl, for Group B2 89.30 mg/dl, and Group B3 93.00 mg/dl respectively. Mean HbA1c results 
for rats after terminal sampling in Group A were 3.71%, Group B1 11.84%, Group B2 4.02%, B3 3.73%. Rats in each 
of Group B2 (Aloe Vera whole leaf treated) and Group B3 (Sitagliptin treated) had a significant reduction in fasting 
blood sugar and HbA1c levels in comparison to Group B1 (diabetic control), with no statistically significant 
intergroup differences in results of Group A, Group B2 and Group B3.  
Conclusion: Aloe Vera whole leaf extract significantly decreased fasting blood glucose and HbA1c levels with 
almost similar efficacy to Sitagliptin in diabetic rats. 
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Introduction 
 
Type 2 diabetes mellitus is considered to be due to 
compromised regulation of carbohydrate, lipid, and 
protein metabolism, and results from either impaired 
insulin secretion, insulin action, or a combination of 
both.1 Different types of oral hypoglycemic agents are 
available for the treatment of type 2 diabetes mellitus, 
including biguanides, sulfonylureas, 
thiazolidinediones, GLP-1 based agents and DPP-4 
inhibitors, etc.2 These agents are given either as a sole 
therapy or in combination.3 
Sitagliptin is 1st amongst DPP-4 inhibitors to get 
approval from the FDA in 2006 for the treatment of 
Type 2 diabetes mellitus.4,5 It is a competitive inhibitor 
of dipeptidyl peptidase-4 (DPP-4) enzyme and exerts 
its antidiabetic effects primarily by suppressing 
glucagon secretion and stimulating insulin release in 
response to a meal-induced rise in incretin hormones 
namely, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP).6,7 
Sitagliptin extends the duration of action of these 
incretins for several hours by slowing their rate of 
degradation.8 Further, DPP-4 inhibitors are neutral to 
the body weight.9 
Oral hypoglycemics used either as monotherapy or in 
combination form, eventually fail to meet the patient’s 
normoglycemic needs. In addition to economic 
constraints, reported side effects of these modern 
drugs encouraged us to search for an economical and 
safe alternative.10 Aloe Barbadensis Miller, commonly 
known as Aloe Vera, belonging to the Liliaceae family, 
is a semitropical to tropical, perennial, succulent 
xerophyte with more than 200  ingredients of which 
over 75 are biologically active compounds..11,12  It has a 
great history of use in folk medicine for over 2000 
years, and has remained an important part of 
traditional medicine of diverse cultures, such as China, 
India, the West Indies, and Japan.13 Its leaf exudate 
and mucilaginous gel hold anti-inflammatory, 
antioxidant, antibacterial, antifungal, anticancer, cyto-
protective, immune-modulatory, and cardiac 
stimulatory activities.14 Till recently, no toxicity is 
reported in manuscripts, of various  Aloe-Vera extract 
preparations, used commercially.15 In the present 
study, comparative antidiabetic effects of Aloe Vera 
whole leaf extract with new antidiabetic drug 
Sitagliptin were observed. As far as we know, no 
comparative studies on antidiabetic effects of Aloe Vera 
whole leaf with sitagliptin are done to date and 
current work will certainly be a useful tool to bridge 
this gap in the struggle of finding a better cure for 
diabetes. 
 
Materials and Methods 
 
The Randomized control trial (RCT) was carried out at 
the Pharmacology Department of Islamic International 
Medical College, Rawalpindi in collaboration with the 
National Institute of Health (NIH) Islamabad for one 
year (September 2019-August 2020). A total of 40 adult 
albino rats, weighing 200-250g were procured from the 
animal house of NIH. All the animals were housed in 
standard cages under standard laboratory conditions: 
temperature 22 ± 2°C, relative humidity 70 ± 4%, and 
12 hours light/dark cycle. 10 rats received a normal 
standard diet and the remaining 30 rats received a 
high-fat standard diet (protein=20%, 
carbohydrates=20%, lipids=60%) which was prepared 
at  NIH and administered as standard food pellets 
manufactured according to the recommendations 
approved by the universities federation for animal 
welfare.16 The care and handling of rats were in 
accordance with the internationally accepted standard 
guidelines for use of animals. After acclimatization for 
1 week, the rats were randomly divided into two main 
groups; 10 rats were allocated to group A and the rest 
of them (30) were allocated to the experimental group 
B. Group A was labelled as Normal Control and was 
given normal saline and normal standard diet whereas 
the Experimental group was given high-fat standard 
diet for two weeks. After diabetes induction Group B 
was further subdivided into three groups with n=10, 
Group B1 (diabetic control), Group B2 (Aloe Vera 
whole leaf treated), and Group B3 (Sitagliptin treated). 
Streptozotocin Catalogue number 4191002-1 (714986), 
CAS No. 18883-66-4, Brand bio world the USA, was 
purchased from a commercial supplier, as a dry-
frozen, pale yellow, sterilized product and kept in a 
freezer to prevent desiccation. Immediately before 
injection, STZ was dissolved in the 50mM sodium 
citrate buffer (pH 4.5). As  STZ is liable to degradation 
within 15 to 20 min after dissolving in the citrate 
buffer, the STZ solution was prepared just before use 
and injected within 5 min of dissolution17. Animals fed 
on the high-fat diet for 2 weeks before this procedure 
and kept overnight fast before injecting streptozotocin. 
A single intraperitoneal injection of streptozotocin at 
the dose of 35 mg/kg body weight was given. The 
fasting blood glucose levels were recorded, after 72 
hours of streptozotocin administration to confirm 
Diabetes. Rats with fasting blood glucose equal and 
above 250 mg/dl were considered diabetic.  
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Research grade Sitagliptin, Batch No: M-20191010-
D05-M06-01 was provided by CCL Pharmaceuticals, 
Lahore, Pakistan on special request. The drug was 
administered orally at the dose of 10 mg/kg body 
weight/day for 40 days.18 Young 2-3 years old, healthy 
Aloe Vera was bought from a local nursery. Plant 
material identification was done at Herbarium of 
Pakistan Quaid-e-Azam University Islamabad, by the 
Department of Plant Sciences. Accession Number is 
132644 and Voucher Specimen Number 125 is 
preserved at Herbarium of Pakistan (ISL) Quaid-e-
Azam University Islamabad Pakistan. For powder 
formation fresh long Aloe Vera leaves were thoroughly 
washed under tap water, thorny edges were removed, 
and the yellow material coming out of the cut end was 
wasted. 1-2 inches from the base and 3-4 inches from 
the tip was removed. Then thin slices of the whole leaf 
were made and put in a big tray and dried19 in the sun. 
After 5 days these slices were completely dried up and 
the powder was obtained after grinding them 
thoroughly, and stored in a tightly closed glass jar, 
under cool, dry, and dark conditions. Later it was used 
in the experiment, mixed in feed made for rats (food 
pellets), at the calculated dose (300 mg/kg body 
weight/day)20, through the oral route, for 40 days, to 
treat Diabetes in an experimental rat model. 
After completion of the study, at Day 60, blood 
samples were taken through the cardiac puncture; FBS 
and HbA1c were measured for all rats in all groups. 
Microlab 300, a semi-automated, clinical chemistry 
analyzer was used for estimation of Fasting Blood 
Sugar, after enzymatic oxidation by glucose oxidase 
method. For HbA1c estimation, Quo–Lab HbA1c, the 
semi-automated analyzer was used. Statistical analysis 
was done by applying the statistical package for Social 
Sciences version 25 (SPSS-25). Results were 
documented as mean + SEM. Comparisons of 
quantitative parameters among the four groups were 
analyzed by using one-way ANOVA (post hoc turkey 





At the start of the study, levels of Fasting Blood 
glucose and HbA1c were comparable to each other in 
all groups. After two weeks of dietary manipulations 
and then administration of Streptozotocin single I/P 
injection at a low dose of 35 mg/kg, diabetes was 
successfully induced in experimental group B. After 
two weeks of treatment, a significant reduction in 
Fasting Blood Glucose was observed in both, Group B2 
and B3 as compared to Diabetic Control Group B1, P-
value <0.001.No significant difference in results of 
FBS, in Group B2 and Group B3, was noted, P-value > 
0.05. After completion of the study, at day 60, mean 
FBS values for rats in Group A were 82.40 mg/dl, for 
Group B1 498.40 mg/dl, for Group B2 89.30 mg/dl, 
and Group B3 93.00 mg/dl respectively. Mean HbA1c 
results for rats after terminal sampling in Group A 
were 3.71%, Group B1 11.84%, Group B2 4.02%, B3 
3.73%. Rats in each of Group B2 (Aloe Vera whole leaf 
treated) and Group B3 (Sitagliptin treated) had a 
significant reduction in fasting blood sugar and HbA1c 
levels in comparison to the Group B1 (diabetic 
control), P-value<0.001, with no statistically significant 
intergroup differences in results of Group A, Group B2 
and Group B3, P-value >0.05. 
 
Table 1: Mean Value + SEM (Standard Error of 
Mean) of Fasting Blood Glucose (mg/dl) on Day 60 

















Mean 82.40 498.40 89.30 93.00 
SEM 7.65 21.72 8.91 3.37 
P-Value                           < 0.001* 
 
Table 2: Mean Value + SEM (Standard Error of 
Mean) of Fasting Blood Glucose (mg/dl) on Day 60 
(n = 40) 
Groups Mean Difference P-Value 
A vs B1 416.00 + 5.57 < 0.001* 
A vs B2 6.90 + 5.57 0.607 
A vs B3 10.60 + 5.57 0.245 
B1 vs B2 242.70 + 5.57 < 0.001* 
B1 vs B3 239.80 + 5.57 < 0.001* 
B2 vs B3 2.90 + 5.57 0.910 
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Figure 1: Serum Fasting Blood Glucose (mg/dl) at 
Day 60 
 
Table 3: Mean Value + SEM (Standard Error of 
Mean) of Serum HbA1c (%) on Day 60 

















Mean 3.71 11.84 4.02 3.73 
SEM 0.11 0.27 0.09 0.34 
P-Value                          < 0.001* 
 
Table 4: Comparison of Mean + SEM (Standard Error 
of Mean) of HbA1c (%) on Day 60 
(n = 40) 
Groups Mean Difference P-Value 
A vs B1 8.13 + 0.22 < 0.001* 
A vs B2 0.31 + 0.22 0.490 
A vs B3 0.02 + 0.22 1.000 
B1 vs B2 7.82 + 0.22 < 0.001* 
B1 vs B3 8.11 + 0.22 < 0.001* 
B2 vs B3 0.29 + 0.22 0.546 
 
 




Aloe Vera, an evergreen, cactus-like plant native to 
South Africa is being used since ancient times for the 
cure of various diseases. Several studies have been 
conducted to demonstrate the useful effects of Aloe 
Vera on diabetes cure. The hypoglycemic activity of 
Aloe Vera is postulated to be due to inhibition of 
hepatic glucose synthesis and an increase in muscle 
glucose utilization. Aloe Vera is richly supplied with 
minerals, mainly magnesium, calcium, sodium, zinc, 
and chromium along with proteins and lipids. These 
minerals are often remembered as hypoglycemic 
elements as they modulate glucose metabolism. 
Chromium aids further through increasing insulin-
mediated glucose uptake by the cells. Also, the high 
content of calcium in Aloe Vera stimulates beta cells of 
the pancreas to release insulin and raises hepatic 
insulin and glycogen concentrations.21 Aloe Vera 
safeguards beta cells from destruction and recovers 
the partly damaged β cells.22 The present study was so 
designed to bring Aloe Vera’s extremely useful 
metabolic effects in diabetes control under the 
limelight. 
The consequences of the present study are in 
accordance with the useful work by Meena Gul et al., 
who conducted RCT to measure the synergistic effects 
of Aloe Vera whole leaf and rosiglitazone on plasma 
glucose, oxidative stress, and lipid profile in Type-2 
Diabetic Sprague-Dawley rats. They induced Type-2 
Diabetes in their experimental rats by feeding them on 
a high-fat diet for two weeks and then a single 
intraperitoneal injection of streptozotocin at the dose 
of 35 mg/kg body weight was given. After diabetes 
induction, rats were randomly divided into two 
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groups and given treatment for 21 days. The diabetic 
treatment group received a combination of Aloe Vera 
whole leaf extract 150 mg/kg and rosiglitazone 2.5 
mg/kg body weight through the I/P route. After 
treatment with this combination plasma glucose, 
serum triglycerides, cholesterol, LDL, and VLDL were 
significantly reduced in these rats as compared to the 
diabetic control group.16 In our study, we similarly 
found a significant reduction in fasting blood glucose 
levels of rats of Group B2 who received Aloe Vera 
whole leaf extract, in comparison to Diabetic Control 
Group B1, P value less than 0.001. 
Enas Ali Kamel Mohamed studied Antidiabetic, 
Antihypercholestermic and Antioxidative Effect of 
Aloe Vera Extract in Alloxan Induced Diabetic Albino 
Rats and reported that Aloe Vera extracts resulted in a 
significant reduction in serum glucose, total 
cholesterol and triacylglycerol levels in those rats and 
on trace element analysis of Aloe Vera extract he found 
that Aloe Vera extracts enclosed substantial amount of 
Chromium, Manganese and Zinc that may lead to the 
antidiabetic activity of this medicinal herb.23  
The present study is also supported by the work of 
Manjunath K et al., on Aloe Vera whole leaf extract, 
determining its hypoglycemic effects in alloxan-
induced diabetes in albino rats. They found that after 
five weeks of treatment with Aloe Vera leaf extract, the 
glycemic control was tremendous, as shown by a 
significant decrease in blood glucose levels in 
experimental rats.24 
Dr. Joyamma John did his experiment to establish 
hypoglycemic effects of Aloe Vera whole leaf extract on 
alloxan-induced diabetic albino rats. He reported that 
aqueous leaf extract of Aloe Vera is a beneficial and 
safe agent in modulating hyperglycemia induced by 
alloxan in an experimental rat model.14 This work 
further supports the findings of the present study 
where hyperglycemia was significantly reduced by 




Due to time constraints and availability issues, serum 
insulin levels, random blood sugar levels, and 
histopathological studies of the pancreas of 




Aloe Vera whole leaf extract and Sitagliptin 
significantly lowered fasting blood glucose and HbA1c 
levels in HFD-STZ–T2DM rat model, P-value <0.001. 
Aloe Vera whole leaf extract had almost similar efficacy 
to Sitagliptin with minor statistically insignificant 
differences (P-value>0.05) in treating diabetes in HFD-
STZ–T2DM rat model. Therefore, Aloe Vera whole leaf 
extract and Sitagliptin may be used interchangeably in 
the treatment of Type 2 diabetes mellitus. This will 
help patients to attain optimum levels of blood glucose 
and HbA1c, through safe, cost-effective, easily 
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